MXPA05012421A - Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos. - Google Patents

Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.

Info

Publication number
MXPA05012421A
MXPA05012421A MXPA05012421A MXPA05012421A MXPA05012421A MX PA05012421 A MXPA05012421 A MX PA05012421A MX PA05012421 A MXPA05012421 A MX PA05012421A MX PA05012421 A MXPA05012421 A MX PA05012421A MX PA05012421 A MXPA05012421 A MX PA05012421A
Authority
MX
Mexico
Prior art keywords
immunomers
chemotherapeutic agents
cancer
conjunction
synergistic treatment
Prior art date
Application number
MXPA05012421A
Other languages
English (en)
Spanish (es)
Inventor
Daqin Wang
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05012421(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hybridon Inc filed Critical Hybridon Inc
Publication of MXPA05012421A publication Critical patent/MXPA05012421A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA05012421A 2003-05-16 2004-05-14 Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos. MXPA05012421A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47124703P 2003-05-16 2003-05-16
PCT/US2004/015313 WO2004103301A2 (en) 2003-05-16 2004-05-14 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MXPA05012421A true MXPA05012421A (es) 2006-02-22

Family

ID=33476820

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012421A MXPA05012421A (es) 2003-05-16 2004-05-14 Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.

Country Status (8)

Country Link
US (3) US7569554B2 (https=)
EP (1) EP1628531A4 (https=)
JP (1) JP2006528697A (https=)
KR (1) KR20060012622A (https=)
AU (1) AU2004241093B2 (https=)
CA (1) CA2526212C (https=)
MX (1) MXPA05012421A (https=)
WO (1) WO2004103301A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
AU9475001A (en) * 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
CA2451974C (en) 2001-06-21 2014-10-14 Karen L. Fearon Chimeric immunomodulatory compounds and methods of using the same
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
WO2007004977A1 (en) 2005-07-01 2007-01-11 Index Pharmaceuticals Ab Immunostimulatory method
PL2179737T3 (pl) 2005-07-01 2014-01-31 Index Pharmaceuticals Ab Sposób do modulowania wrażliwości na steroidy
WO2007024921A2 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
ES2544877T3 (es) * 2005-10-12 2015-09-04 Idera Pharmaceuticals Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
CA2625969A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
GB0523041D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
DK2073837T3 (da) * 2006-10-06 2014-09-29 Bavarian Nordic Inc Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
NZ589719A (en) 2008-06-09 2012-08-31 Cyclacel Ltd Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
KR20120054069A (ko) * 2009-08-14 2012-05-29 로슈 글리카트 아게 플루다라빈 및/또는 미토잔트론과 어푸코실화된 ｃｄ20 항체의 복합 요법
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
CN102172359A (zh) * 2011-03-02 2011-09-07 张始状 腺苷与核苷组合在制备治疗肿瘤药物中的应用
HUE046177T2 (hu) 2011-04-14 2020-02-28 Cyclacel Ltd Szapacitabin és decitabin kombinációjának adagolási rendje akut mieloid leukémia kezelésére
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
KR20170078843A (ko) 2014-11-21 2017-07-07 노오쓰웨스턴 유니버시티 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
TW244371B (https=) * 1992-07-23 1995-04-01 Tri Clover Inc
US6346614B1 (en) * 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
AU2092597A (en) * 1996-03-07 1997-09-22 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
US5912332A (en) * 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
US6581606B2 (en) * 1999-07-06 2003-06-24 The Rx Files Corporation Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response
DK1200580T3 (da) 1999-08-13 2005-04-11 Hybridon Inc Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
AU785212B2 (en) * 1999-12-13 2006-11-09 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
EP1311288A1 (en) * 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
DE60132170T2 (de) 2000-01-26 2008-12-18 Idera Pharmaceuticals, Inc., Cambridge MODULIERUNG DER DURCH CpG-OLIGONUKLEOTIDE VERURSACHTEN IMMUNSTIMULIERUNG DURCH POSITIONSBEDINGTE VERÄNDERUNG VON NUKLEOSIDEN
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
AU5736601A (en) 2000-05-01 2001-11-12 Hybridon Inc Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
AU2001270134B2 (en) * 2000-06-22 2006-06-15 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
AU9475001A (en) * 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
ATE398175T1 (de) * 2000-12-08 2008-07-15 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
CA2451974C (en) 2001-06-21 2014-10-14 Karen L. Fearon Chimeric immunomodulatory compounds and methods of using the same
EP1501359A4 (en) * 2001-08-03 2007-04-18 Celldex Therapeutics Inc IMMUNOSTIMULATING OLIGONUCLEOTIDE-CONTAINING COMPOSITIONS AND USES THEREOF FOR IMPROVING FC-RECEPTOR-MEDIATED IMMUNOTHERAPIES
WO2003035836A2 (en) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
AU2004206820B2 (en) * 2003-01-16 2010-06-10 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
US20060014713A1 (en) * 2004-06-15 2006-01-19 Hybridon, Inc. Immunostimulatory oligonucleotide multimers

Also Published As

Publication number Publication date
EP1628531A2 (en) 2006-03-01
JP2006528697A (ja) 2006-12-21
EP1628531A4 (en) 2010-06-30
US20080206265A1 (en) 2008-08-28
CA2526212A1 (en) 2004-12-02
WO2004103301A2 (en) 2004-12-02
AU2004241093B2 (en) 2009-08-27
US7875594B2 (en) 2011-01-25
WO2004103301A3 (en) 2005-11-03
US7569554B2 (en) 2009-08-04
US20050009773A1 (en) 2005-01-13
KR20060012622A (ko) 2006-02-08
CA2526212C (en) 2013-08-27
US20120107303A1 (en) 2012-05-03
AU2004241093A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
TW200612918A (en) Lonidamine analogs
ATE430570T1 (de) Synergistische kombinationstherapie zur krebsbehandlung
SG145699A1 (en) Pyridazine derivatives and their use as therapeutic agents
IL164599A0 (en) Combination therapy for the treatment of cancer
EP1648913A4 (en) SYNERGISTIC STIMULATION OF THE IMMUNE SYSTEM WITH IMMUNOSTIMULATING OLIGONUCLEOTIDES AND / OR IMMUNOMER COMPOUNDS RELATED TO CYTOKINES AND / OR CHEMOTHERAPEAN MEDICAMENTS OR RADIATION THERAPY
NO20054988D0 (no) Preparater og metoder for behandling av cancer
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
SG145695A1 (en) Pyridyl derivatives and their use as therapeutic agents
IL182652A0 (en) Nitrobenzindoles and their use in cancer therapy
IL166475A0 (en) Improved treatment of cancer with glutamine
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
PL369148A1 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
UA87877C2 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
HUP0300339A3 (en) Use of fulvestrant in the treatment of resistant breast cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
HUP0203153A2 (hu) Kombinációs kemoterápia
AU2003274963A8 (en) Mda-7 and free radicals in the treatment of cancer
GB0326578D0 (en) Cancer diagnosis and therapy
MXPA02012911A (es) Compuestos de rutenio (ii) para el uso en terapia del cancer.
SG112006A1 (en) Radioactive arsenic-containing compounds and their uses in the treatment of tumors
AU2003231803A8 (en) Treatment of cancer with mefloquire
EP1583543A4 (en) METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer

Legal Events

Date Code Title Description
FG Grant or registration